LIMINATUS PHARMA, INC. Increase (Decrease) in Accrued Liabilities
LIMINATUS PHARMA, INC. (LIMN) reported Increase (Decrease) in Accrued Liabilities of $255 for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-06-02.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2025-06-02
- LIMINATUS PHARMA, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-03-31 was $255.00, a 3.24% increase year-over-year.
- LIMINATUS PHARMA, INC. increase (decrease) in accrued liabilities for the quarter ending 2024-03-31 was $247.00.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month |
|---|---|
| 2025-03-31 | $255.00 10-Q · filed 2025-06-02 |
| 2024-03-31 | $247.00 10-Q · filed 2025-06-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |